Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.

E. Richelson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.

Original languageEnglish (US)
Pages (from-to)17-30
Number of pages14
JournalClinical Cornerstone
Volume1
Issue number4
StatePublished - 1999

Fingerprint

Neuropharmacology
Antidepressive Agents
Depression
Drug Therapy
Pharmaceutical Preparations
Obsessive-Compulsive Disorder
United States Food and Drug Administration
Pharmacology
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression. / Richelson, E.

In: Clinical Cornerstone, Vol. 1, No. 4, 1999, p. 17-30.

Research output: Contribution to journalArticle

@article{c35bbf8ee473421fa034f5f6db48c2d4,
title = "Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.",
abstract = "In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.",
author = "E. Richelson",
year = "1999",
language = "English (US)",
volume = "1",
pages = "17--30",
journal = "Clinical Cornerstone",
issn = "1098-3597",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.

AU - Richelson, E.

PY - 1999

Y1 - 1999

N2 - In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.

AB - In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.

UR - http://www.scopus.com/inward/record.url?scp=0033251486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033251486&partnerID=8YFLogxK

M3 - Article

C2 - 10682175

AN - SCOPUS:0033251486

VL - 1

SP - 17

EP - 30

JO - Clinical Cornerstone

JF - Clinical Cornerstone

SN - 1098-3597

IS - 4

ER -